Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The success of ongoing productivity improvement initiatives and the contribution from the price revisions implemented in June 2025 from the beginning of the fiscal year led to the increase. The capacity to accept patients increased through improvements in medical techniques, the recruitment and training of veterinarians, expansion of medical equipment, and a review of medical treatment workflows.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | 1,644 Millions of yen (YoY +11.6%) |
| Operating profit | 349 Millions of yen (YoY +35.0%) |
| Ordinary income | 347 Millions of yen (YoY +34.6%) |
| Profit attributable to owners of the parent | 239 Millions of yen (YoY +33.0%) |
| Net income per share | ¥18.54 |
| Equity ratio | End of the current fiscal period 44.1 / End of previous period 43.1 |
| Total assets | 11,235 Millions of yen |
| Net assets | 4,957 Millions of yen |
| Full-year earnings forecast | Net Sales 6,600 Millions of yen (YoY +6.6%) / Operating profit 1,270 Millions of yen (YoY +10.4%) / Ordinary income 1,220 Millions of yen (YoY +6.8%) / Net income 890 Millions of yen (YoY +6.8%) / Net income per share ¥68.86 |
| Revision to Earnings Forecast | Not disclosed |
| Annual Dividend Forecast | ¥12 → ¥13（+8.3%） |
| Segment revenue | Segment Animal healthcare-related business / Net Sales Not disclosed / Year on year against the same period last year Not disclosed |
| Segment profit | Segment Animal healthcare-related business / Segment profit Not disclosed / Year on year against the same period last year Not disclosed |
| Depreciation and amortization | ¥117,343 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate Yes / Restatement No |
| Changes in the scope of consolidation | New Not disclosed / Excluded Not disclosed / Description Significant changes in the scope of consolidation during the cumulative consolidated third-quarter period: No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 14,391,000 |
| Treasury Shares at Period-End | 1,466,240 |
| Factors Behind Changes in Business Performance | The success of ongoing productivity improvement initiatives and the contribution from the price revisions implemented in June 2025 from the beginning of the fiscal year led to the increase. The capacity to accept patients increased through improvements in medical techniques, the recruitment and training of veterinarians, expansion of medical equipment, and a review of medical treatment workflows. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This was due to the success of ongoing productivity improvement initiatives and the contribution from the price revisions implemented in June 2025 from the beginning of the fiscal year. In addition, the capacity to accept patients increased through improvements in medical techniques, the recruitment and training of veterinarians, expansion of medical equipment, and a review of medical treatment workflows.